PARALLAX HEALTH SCIENCES, INC. (OTCMKTS:PRLX) Files An 8-K Unregistered Sales of Equity Securities
ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES
The disclosures set forth in Item 3.03 are incorporated by into this Item 3.02 by reference.
ITEM 3.03 MATERIAL MODIFICATION TO RIGHTS OF SECURITY HOLDERS
On March 11, 2019, the Company filed Certificate of Correction(s) (“Corrections”) with the secretary of state of Nevada. The Corrections included a Certificate of Validation, and were made to validate the Certificate of Designations previously filed for the Company’s Series A, Series B and Series C Preferred Stock, and the effective dates therefor.
The following represent a summary of the basic designations and preferences of each series of the Company’s preferred stock:
|
Series |
Shares Issued |
Voting Rights |
Conversion Rate [1] |
Dividend Rate |
|
Series A |
823,691 |
None |
20.000 |
7% |
|
Series B |
40,000 |
None |
20.000 |
10% |
|
Series C |
150,000 |
None |
41.667 [2] |
8% |
|
Total |
1,013,691 |
[1] Number of Common Stock issuable for each share of preferred stock held.
[2] Conversion rate subject to change if not converted within 12 months of issuance of preferred shares.
The foregoing summaries of the Certificates of Designation do not purport to be complete, and are qualified in their entirety by reference to the Certificate of Correction, the Certificate of Validation and the Certificate of Designation for Series A, Series B and Series C Preferred Stock, which are filed as Exhibit 3.6, 3.7 and 3.8, respectively, of this Current Report and incorporated by reference herein.
ITEM 5.02AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.
The disclosures set forth in Item 3.03 are incorporated by into this Item 5.02 by reference.
ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
PARALLAX HEALTH SCIENCES, INC. Exhibit
EX-3 2 ex36certdesignationseriesa….
To view the full exhibit click here
About PARALLAX HEALTH SCIENCES, INC. (OTCMKTS:PRLX)
Parallax Health Sciences, Inc. focuses on personalized patient care through the use of the Company’s Compound Pharmacy (Roxsan, Inc.) and eventually through the diagnostic testing platform capable of diagnosing and monitoring various health issues. The Company’s segments include Retail Pharmacy Services (RPS) and Corporate. The RPS segment provides a range of pharmacy services, including retail, compounding and fertility medications. The Corporate segment provides management and administrative services to support the Company. The RPS segment dispenses prescription drugs, both through local channels by direct delivery, as well as mail order. The RPS segment also sells an assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, seasonal merchandise and convenience foods, through the Company’s pharmacy. It holds interests in Quality of Life Peace of Mind (QOLPOM). The QOLPOM Hub is a personal medication dispensing and remote monitoring solution.
